Qurient Co. Ltd - Asset Resilience Ratio
Qurient Co. Ltd (115180) has an Asset Resilience Ratio of 37.05% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 115180 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Qurient Co. Ltd's Asset Resilience Ratio has changed over time. See 115180 net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Qurient Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Qurient Co. Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩21.31 Billion | 37.05% |
| Total Liquid Assets | ₩21.31 Billion | 37.05% |
Asset Resilience Insights
- Very High Liquidity: Qurient Co. Ltd maintains exceptional liquid asset reserves at 37.05% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Qurient Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Qurient Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Qurient Co. Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Qurient Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 70.62% | ₩46.31 Billion ≈ $31.38 Million |
₩65.57 Billion ≈ $44.44 Million |
-7.24pp |
| 2023-12-31 | 77.86% | ₩40.88 Billion ≈ $27.70 Million |
₩52.50 Billion ≈ $35.58 Million |
+9.74pp |
| 2022-12-31 | 68.12% | ₩26.17 Billion ≈ $17.73 Million |
₩38.41 Billion ≈ $26.03 Million |
+10.09pp |
| 2021-12-31 | 58.03% | ₩33.44 Billion ≈ $22.66 Million |
₩57.62 Billion ≈ $39.05 Million |
-22.76pp |
| 2018-12-31 | 80.80% | ₩34.90 Billion ≈ $23.65 Million |
₩43.20 Billion ≈ $29.27 Million |
+17.69pp |
| 2017-12-31 | 63.10% | ₩9.89 Billion ≈ $6.70 Million |
₩15.68 Billion ≈ $10.62 Million |
+55.48pp |
| 2016-12-31 | 7.62% | ₩2.00 Billion ≈ $1.36 Million |
₩26.24 Billion ≈ $17.78 Million |
-- |
About Qurient Co. Ltd
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more